Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368387 | 1.00 | BDKRB2 (0.38) | BDKRB2ALOX15CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14353201 | 0.79 | BDKRB2 (0.37) | BDKRB2CYP1A2CYP2D6CYP2C19LMNA | |
| SCHEMBL14555208 | 0.79 | ALDH1A1 (0.37) | BDKRB2LMNA | |
| SCHEMBL2368827 | 0.75 | BDKRB2 (0.53) | BDKRB2CYP1A2 | |
| SCHEMBL6817767 | 0.72 | BDKRB2 (0.44) | BDKRB2CYP1A2MAOAMAOB | |
| SCHEMBL21696797 | 0.72 | BDKRB2 (0.44) | BDKRB2MAOAMAOB | |
| SCHEMBL19350978 | 0.71 | LMNA (0.47) | BDKRB2CYP1A2CYP2D6CYP2C19LMNA | |
| SCHEMBL28218741 | 0.71 | SKP2 (0.47) | CYP1A2CYP2D6CYP2C19SKP2 | |
| SCHEMBL28265214 | 0.71 | LMNA (0.47) | BDKRB2CYP1A2CYP2D6CYP2C19LMNA | |
| SCHEMBL20226533 | 0.70 | MAPT (0.46) | BDKRB2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263973-B2 | Anthracene compounds for luminescent applications | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2367900-A2 | ANTHRACENE COMPOUNDS FOR LUMINESCENT APPLICATIONS | E. I. du Pont de Nemours and Company (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100187508-A1 | ANTHRACENE COMPOUNDS FOR LUMINESCENT APPLICATIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010071871-A2 | ANTHRACENE COMPOUNDS FOR LUMINESCENT APPLICATIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100187508-A1 | ANTHRACENE COMPOUNDS FOR LUMINESCENT APPLICATIONS | ANXA2, ANXA1, ANXA3 | BDKRB2 4036/4885ALOX15 874/4885CYP1A2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.